Also known as: Stoke Therapeutics
Stoke Therapeutics is a biotechnology company developing treatments for severe genetic diseases by upregulating protein expression. It uses its TANGO antisense oligonucleotide approach and advances programs including zorevunersen for Dravet syndrome.
New treatments for rare pediatric neurological conditions show promise, with zorevunersen reducing seizures in Dravet syndrome patients and an SMA therapy under FDA review following stem cell research breakthroughs.
Stoke Therapeutics presented long-term Dravet syndrome data showing up to 80% seizure reductions sustained through three years, outlined its Phase 3 EMPEROR trial design targeting mid-2027 data, and disclosed first patient dosing in its ADOA program.
